Korro Q1 net loss $23.4M; workforce reduction of 20%, cash runway into 2027

Korro Bio, Inc.

Net loss $23.4M vs $19.6M YoY; collaboration revenue $2.6M from Novo Nordisk.
Cash, cash equivalents and marketable securities $139.0M, expected to fund operations into 2027.
Workforce reduction of approximately 20%; one-time restructuring charges ~$1.2M in Q2 2025.
Phase 1/2a REWRITE trial interim readout for KRRO-110 expected H2 2025; trial completion in 2026.
Expect to nominate second development candidate in 2025; Novo Nordisk cardiometabolic collaboration ongoing.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.